Abbott Laboratories reported a 1% dip in second quarter diagnostics revenue to $2.17 billion, pressured by falling COVID-19 test sales and China's volume-based procurement impact. Notably, core laboratory sales grew 8% outside China, offsetting declines in molecular and point-of-care segments. CEO Robert Ford indicated ongoing challenges but reaffirmed optimism for the diagnostics and medical devices portfolios. Johnson & Johnson posted $8.54 billion in medical device sales for Q2 with strong growth in cardiology and innovative medicines divisions, despite Stelara biosimilar competition. Both companies navigate headwinds from regulatory and market dynamics while defending growth trajectories.